191 related articles for article (PubMed ID: 12715240)
1. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI.
Mamalaki A; Gritzapis AD; Kretsovali A; Belimezi M; Papamatheakis J; Perez SA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Aug; 52(8):513-22. PubMed ID: 12715240
[TBL] [Abstract][Full Text] [Related]
2. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.
Gritzapis AD; Mamalaki A; Kretsovali A; Papamatheakis J; Belimezi M; Perez SA; Baxevanis CN; Papamichail M
Br J Cancer; 2003 Apr; 88(8):1292-300. PubMed ID: 12698199
[TBL] [Abstract][Full Text] [Related]
3. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Eshhar Z; Waks T; Gross G; Schindler DG
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):720-4. PubMed ID: 8421711
[TBL] [Abstract][Full Text] [Related]
4. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
[TBL] [Abstract][Full Text] [Related]
5. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.
Weijtens ME; Willemsen RA; Valerio D; Stam K; Bolhuis RL
J Immunol; 1996 Jul; 157(2):836-43. PubMed ID: 8752936
[TBL] [Abstract][Full Text] [Related]
6. Redirecting effector T cells through their IL-2 receptors.
Lustgarten J; Marks J; Sherman LA
J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
[TBL] [Abstract][Full Text] [Related]
7. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit.
Annenkov AE; Moyes SP; Eshhar Z; Mageed RA; Chernajovsky Y
J Immunol; 1998 Dec; 161(12):6604-13. PubMed ID: 9862688
[TBL] [Abstract][Full Text] [Related]
8. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
9. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
Lustgarten J
Cancer Immunol Immunother; 2003 Dec; 52(12):751-60. PubMed ID: 12827309
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
[TBL] [Abstract][Full Text] [Related]
11. Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes.
Lustgarten J; Eshhar Z
Eur J Immunol; 1995 Oct; 25(10):2985-91. PubMed ID: 7589102
[TBL] [Abstract][Full Text] [Related]
12. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.
Darcy PK; Kershaw MH; Trapani JA; Smyth MJ
Eur J Immunol; 1998 May; 28(5):1663-72. PubMed ID: 9603473
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
14. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
Darcy PK; Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ
J Immunol; 2000 Apr; 164(7):3705-12. PubMed ID: 10725729
[TBL] [Abstract][Full Text] [Related]
15. Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells.
Demirtzoglou FJ; Papadopoulos S; Zografos G
Immunopharmacol Immunotoxicol; 2006; 28(4):571-90. PubMed ID: 17190735
[TBL] [Abstract][Full Text] [Related]
16. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
[TBL] [Abstract][Full Text] [Related]
17. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski I; Schindler DG; Waks T; Yarden Y; Sela M; Eshhar Z
J Immunol; 1993 Dec; 151(11):6577-82. PubMed ID: 7902379
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz D; Wels W; Mattern J; Groner B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4318-22. PubMed ID: 7910405
[TBL] [Abstract][Full Text] [Related]
20. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
